Evidence map›Paper›PMID 36229903›Full record

ArticleJournal of preventive medicine and public health = Yebang Uihakhoe chi2022

The Primary Process and Key Concepts of Economic Evaluation in Healthcare.

Younhee Kim, Yunjung Kim, Hyeon-Jeong Lee, Seulki Lee, Sun-Young Park, Sung-Hee Oh, Suhyun Jang, Taejin Lee, Jeonghoon Ahn, Sangjin Shin

Open access · goldAbstract read
In one paragraph

Article in Journal of preventive medicine and public health = Yebang Uihakhoe chi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. [Economic evaluation in the health sector: The link between economic and health variables].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. The economic burden of brucellosis in Western Iran.Tropical medicine and health · 2025
    Article
  13. Observational
  14. Review
  15. Economic impact of RSV infections in young children attending primary care: a prospective cohort study in five European countries, 2021 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Younhee KimDepartment of Social Medicine, Inha University College of Medicine, Incheon, Korea.
Yunjung KimDivision of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
Hyeon-Jeong LeeDivision of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
Seulki LeeDivision of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
Sun-Young ParkVIAplus, Suwon, Korea.
Sung-Hee OhBK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea.
Suhyun JangCollege of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea.
Taejin LeeDepartment of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea.
Jeonghoon AhnDepartment of Health Convergence, Ewha Womans University, Seoul, Korea.
Sangjin ShinDivision of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
National Evidenc- based healthcare Collaborating Agency · KRInha University · KREwha Womans University · KRGachon University · KRKyungpook National University · KRSeoul National University · KRSuwon Research Institute · KR

Funding

National Evidence-based Healthcare Collaborating Agency NR20-001National Evidence-based Healthcare Collaborating Agency NR21-001
6 · The paper itself

Abstract

Economic evaluations in the healthcare are used to assess economic efficiency of pharmaceuticals and medical interventions such as diagnoses and medical procedures. This study introduces the main concepts of economic evaluation across its key steps: planning, outcome and cost calculation, modeling, cost-effectiveness results, uncertainty analysis, and decision-making. When planning an economic evaluation, we determine the study population, intervention, comparators, perspectives, time horizon, discount rates, and type of economic evaluation. In healthcare economic evaluations, outcomes include changes in mortality, the survival rate, life years, and quality-adjusted life years, while costs include medical, non-medical, and productivity costs. Model-based economic evaluations, including decision tree and Markov models, are mainly used to calculate the total costs and total effects. In cost-effectiveness or costutility analyses, cost-effectiveness is evaluated using the incremental cost-effectiveness ratio, which is the additional cost per one additional unit of effectiveness gained by an intervention compared with a comparator. All outcomes have uncertainties owing to limited evidence, diverse methodologies, and unexplained variation. Thus, researchers should review these uncertainties and confirm their robustness. We hope to contribute to the establishment and dissemination of economic evaluation methodologies that reflect Korean clinical and research environment and ultimately improve the rationality of healthcare policies.

Indexed as

Delivery of Health CareCost-Benefit AnalysisHumansPharmaceutical PreparationsQuality-Adjusted Life YearsPharmaceutical PreparationsDecision treesEconomic evaluationIncremental cost-effective ratioMarkov modelMedical costQuality-adjusted life year

Identifiers

PMID36229903
PMCPMC9561137
OpenAlexW4293027748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.